Evolus, Inc. News Releases https://investors.evolus.com/ Evolus, Inc. News Releases en Evolus Provides Update on Nuceiva™ Marketing Authorization Application in Europe https://investors.evolus.com/news-releases/news-release-details/evolus-provides-update-nuceivatm-marketing-authorization NEWPORT BEACH, Calif. , June 10, 2019 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS) today provided an update on the marketing authorization application (MAA) for Nuceiva™ in Europe that may result in the European Commission (EC) extending its final decision on approval beyond the 90 days Mon, 10 Jun 2019 09:00:00 -0400 Evolus, Inc. News Releases 7461 Evolus Accelerates Next Phase of U.S. Launch of Jeuveau™ with ‘#NEWTOX NOW’ Consumer Conversion Program https://investors.evolus.com/news-releases/news-release-details/evolus-accelerates-next-phase-us-launch-jeuveautm-newtox-now NEWPORT BEACH, Calif. , June 05, 2019 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS) today announced the launch of the ‘#NEWTOX NOW’ consumer conversion program following the rapid adoption of the company’s Jeuveau™ Experience Treatment (J.E.T.) program. Wed, 05 Jun 2019 07:45:00 -0400 Evolus, Inc. News Releases 7456 Evolus to Participate in Three Upcoming Investor Conferences https://investors.evolus.com/news-releases/news-release-details/evolus-participate-three-upcoming-investor-conferences NEWPORT BEACH, Calif. , May 28, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that members of management will be participating in three upcoming investor conferences in Tue, 28 May 2019 16:01:00 -0400 Evolus, Inc. News Releases 7421 Evolus Announces First Shipment of Jeuveau™ (prabotulinumtoxinA-xvfs) to Customers in the United States https://investors.evolus.com/news-releases/news-release-details/evolus-announces-first-shipment-jeuveautm-prabotulinumtoxina Jeuveau™ Experience Treatment (J.E.T.) Planned to Rollout to Approximately 3,000 Practices Nation-wide NEWPORT BEACH, Calif. , May 15, 2019 (GLOBE NEWSWIRE) -- Evolus , Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, Wed, 15 May 2019 09:00:00 -0400 Evolus, Inc. News Releases 7361 Evolus Reports First Quarter 2019 Financial Results https://investors.evolus.com/news-releases/news-release-details/evolus-reports-first-quarter-2019-financial-results U.S. Sales Force Hired and Trained with U.S Launch of Jeuveau™ Imminent NEWPORT BEACH, Calif. , April 30, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today reported financial results Tue, 30 Apr 2019 16:01:00 -0400 Evolus, Inc. News Releases 7336 Evolus to Participate in Two Upcoming Investor Conferences https://investors.evolus.com/news-releases/news-release-details/evolus-participate-two-upcoming-investor-conferences-1 IRVINE, Calif. , April 29, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that members of management will be participating in two upcoming investor conferences. Mon, 29 Apr 2019 08:00:00 -0400 Evolus, Inc. News Releases 7306 Evolus Receives Positive CHMP Opinion for Nuceiva™ in the European Union https://investors.evolus.com/news-releases/news-release-details/evolus-receives-positive-chmp-opinion-nuceivatm-european-union European Commission Approval Anticipated Within 90 Days NEWPORT BEACH, Calif. , April 26, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced the European Medicines Agency’s Fri, 26 Apr 2019 08:50:00 -0400 Evolus, Inc. News Releases 7296 Evolus to Release First Quarter 2019 Financial Results and Provide a Business Update on Tuesday, April 30, 2019 https://investors.evolus.com/news-releases/news-release-details/evolus-release-first-quarter-2019-financial-results-and-provide IRVINE, Calif. , April 24, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will release first quarter 2019 financial results and provide a business update after Wed, 24 Apr 2019 16:05:00 -0400 Evolus, Inc. News Releases 7291 Evolus Announces Publication of Largest Aesthetic Head-to-Head Pivotal Trial Comparing Jeuveau™ and BOTOX® in Aesthetic Surgery Journal https://investors.evolus.com/news-releases/news-release-details/evolus-announces-publication-largest-aesthetic-head-head-pivotal Primary Endpoint of Non-Inferiority Achieved with Responder Rates* of 87.2% for Jeuveau™, 82.8% for BOTOX ® and 4.2% for Placebo at Day 30 Secondary and Exploratory Analyses Unveil Additional Information about Jeuveau™ Clinical Performance  Thirty New Exploratory Head-to-Head Data Points Conference Mon, 08 Apr 2019 07:00:00 -0400 Evolus, Inc. News Releases 7251 Evolus Provides Regulatory Update on Nuceiva™ in the European Union https://investors.evolus.com/news-releases/news-release-details/evolus-provides-regulatory-update-nuceivatm-european-union NEWPORT BEACH, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced it expects the European Medicines Agency (EMA) Committee for Medicinal Products for Mon, 01 Apr 2019 09:00:00 -0400 Evolus, Inc. News Releases 7226